Benefits of the Action include:
- Improving the health of EU citizens by concerted action of multidisciplinary EU research groups on 1) evaluating the risk of NCC and taeniosis within the EU (via immigration/ travel or autochthonous transmission), 2) identifying common actions for prevention and control, 3) identifying and advocating for an improved surveillance system, and 4) NCC management (diagnosis, treatment).
- Reducing the negative economic impact on both health and meat sectors
- Obtaining the global burden of disease estimates, which are urgently needed to inform public authorities and advocate for more funding both for research and for control/prevention
- An increased communication between Medical and Veterinary Sectors.
- Benefits to other Cysticercosis Working groups, mainly in endemic developing countries, by providing scientific support
- Creating opportunities for EU diagnostic companies (private sector) to further develop innovative diagnostic tools, new drugs/formulations, vaccines
- Technological advancement by technology exchange, especially in the field of genome, proteomics, nanobody technology; and sharing of biological databanks
- Research mobility of young researchers by exchange visits in top-level laboratories/research centres within and outside EU.
The Action is aimed at both European economical/societal needs and scientific/technological advances.